BEAM
Price
$24.85
Change
+$0.23 (+0.93%)
Updated
May 20, 1:28 PM EST
78 days until earnings call
ERAS
Price
$2.00
Change
+$0.04 (+2.03%)
Updated
May 20, 9:45 AM EST
80 days until earnings call
Ad is loading...

BEAM vs ERAS

Header iconBEAM vs ERAS Comparison
Open Charts BEAM vs ERASBanner chart's image
Beam Therapeutics
Price$24.85
Change+$0.23 (+0.93%)
Volume$143
CapitalizationN/A
Erasca
Price$2.00
Change+$0.04 (+2.03%)
Volume$4.31K
CapitalizationN/A
View a ticker or compare two or three
BEAM vs ERAS Comparison Chart

Loading...

BEAMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ERASDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
BEAM vs. ERAS commentary
May 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and ERAS is a Hold.

COMPARISON
Comparison
May 20, 2024
Stock price -- (BEAM: $24.62 vs. ERAS: $1.97)
Brand notoriety: BEAM and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 99% vs. ERAS: 1336%
Market capitalization -- BEAM: $2.03B vs. ERAS: $341.52M
BEAM [@Biotechnology] is valued at $2.03B. ERAS’s [@Biotechnology] market capitalization is $341.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $586.12B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both BEAM and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 3 bearish.
  • ERAS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ERAS.

Price Growth

BEAM (@Biotechnology) experienced а +15.80% price change this week, while ERAS (@Biotechnology) price change was +6.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.97%. For the same industry, the average monthly price growth was +5.94%, and the average quarterly price growth was +64.32%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 06, 2024.

ERAS is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+1.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BEAM with price predictions.
OPEN
A.I.dvisor published
a Summary for ERAS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BEAM($2.03B) has a higher market cap than ERAS($342M). ERAS YTD gains are higher at: -7.512 vs. BEAM (-9.552).
BEAMERASBEAM / ERAS
Capitalization2.03B342M592%
EBITDAN/AN/A-
Gain YTD-9.552-7.512127%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
BEAMERAS
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 19 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
View a ticker or compare two or three
Ad is loading...
BEAMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ERASDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSKLX7.860.11
+1.42%
Morgan Stanley Inst Discovery L
HSUCX28.510.07
+0.25%
Rational Dynamic Brands C
GCECX16.590.04
+0.24%
AB Global Core Equity C
WFSPX622.450.75
+0.12%
iShares S&P 500 Index K
RYMCX8.37-0.02
-0.24%
Royce Micro-Cap Consult

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+6.49%
XNCR - ERAS
43%
Loosely correlated
+2.54%
NTLA - ERAS
43%
Loosely correlated
+0.19%
GLUE - ERAS
41%
Loosely correlated
-0.38%
BEAM - ERAS
40%
Loosely correlated
+3.49%
TNYA - ERAS
38%
Loosely correlated
+9.65%
More